Ginkgo biloba and Cashew Applications
Ginkgo biloba, one of the oldest surviving tree species, has attracted sustained scientific attention for its standardized leaf extracts, which contain two main active compound classes — flavonoids and terpene trilactones — that appear to protect neurons from oxidative damage and support cerebral blood flow. Researchers in complementary and alternative medicine are investigating whether these properties translate into meaningful clinical benefits for people with mild cognitive impairment, dementia, or Alzheimer's disease, conditions for which conventional pharmacology still offers limited options. A central challenge is understanding the pharmacokinetics of these compounds well enough to establish reliable dosing, since absorption, metabolism, and bioavailability vary considerably across individuals and formulations. Ongoing work is also trying to determine whether Ginkgo biloba acts best as a preventive agent in healthy aging populations or as a therapeutic adjunct once cognitive decline is already underway.
- Works
- 24,851
- Total citations
- 229,235
- Keywords
- Ginkgo BilobaNeuroprotectiveDementiaAntioxidantCognitive ImpairmentAlzheimer's Disease
Top papers in Ginkgo biloba and Cashew Applications
Ordered by total citation count.
- Association of single nucleotide polymorphisms in the lens epithelium-derived growth factor (LEDGF/p75) with HIV-1 infection outcomes in brazilian HIV-1+ individuals↗ 7,021OA
- Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study↗ 4,352OA
- Clinical diagnostic criteria for dementia associated with Parkinson's disease↗ 3,013
- Antioxidant Activity and Phenolic Compounds in Selected Herbs↗ 2,865
- Diagnostic criteria for mild cognitive impairment in Parkinson's disease: <i>Movement</i> Disorder Society Task Force guidelines↗ 2,500OA
- Dietary (Poly)phenolics in Human Health: Structures, Bioavailability, and Evidence of Protective Effects Against Chronic Diseases↗ 2,484OA
- Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030↗ 2,456
- The Parkinson Progression Marker Initiative (PPMI)↗ 1,864OA
- Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment↗ 1,856OA
- The Hawthorne Effect: a randomised, controlled trial↗ 1,697OA
- Editorial on Consensus Recommendations for the Postmortem Diagnosis of Alzheimer Disease from the National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer Disease↗ 1,559OA
- Folate, Vitamin B12, and Serum Total Homocysteine Levels in Confirmed Alzheimer Disease↗ 1,414
Active researchers
Top authors in this area, ranked by h-index.